Malignant hyperthermia: clinical and molecular aspects

Area of Science:

• Pharmacogenetics
• Molecular Biology
• Channelopathies

Background:

• Malignant hyperthermia (MH) is a life-threatening pharmacogenetic disorder.
• Susceptibility is linked to mutations in the skeletal muscle ryanodine receptor (RyR1), affecting calcium homeostasis.
• Triggers include anesthetics, muscle relaxants, and extreme physical activity.

Purpose of the Study:

• To review the molecular and clinical aspects of malignant hyperthermia.
• To highlight the role of RyR1 in MH pathogenesis.
• To discuss advances in diagnosis and treatment.

Main Methods:

• Review of existing literature on malignant hyperthermia.
• Integration of molecular genetics findings with clinical manifestations.
• Discussion of diagnostic methods and therapeutic strategies.

Main Results:

• The ryanodine receptor of skeletal muscle (RyR1) is the primary genetic locus for MH susceptibility.
• Mutations in the RYR1 gene are associated with MH, but other genes may also be involved.
• Current diagnosis relies on the halothane-caffeine contracture test (CHCT), and treatment involves dantrolene.

Conclusions:

• Advances in molecular genetics offer potential for developing less invasive DNA-based diagnostic tests for MH.
• Further understanding of MH pathophysiology may lead to novel therapeutic strategies.
• Integrating molecular and clinical data is crucial for improved management of MH.